- Maze Therapeutics SVP, Finance Amy Bachrodt reported sales of 2,500 shares on April 1, 2026.
- Disposals totaled 2,200 shares at $29.32 per share, weighted average.
- Additional 300 shares were sold at $30.34 per share, weighted average.
- Holdings fell to 12,965 shares following transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002050422-26-000012), on April 02, 2026, and is solely responsible for the information contained therein.
Comments